Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SUTRO BIOPHARMA, INC. Director's Dealing 2025

Mar 5, 2025

34319_dirs_2025-03-04_ad003827-8bd9-41e1-aa74-2a6c9ed58001.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SUTRO BIOPHARMA, INC. (STRO)
CIK: 0001382101
Period of Report: 2025-03-01

Reporting Person: ALBINI EDWARD C (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-03-01 Common Stock M 7875 Acquired 114618 Direct
2025-03-01 Common Stock M 17250 Acquired 131868 Direct
2025-03-01 Common Stock F 10320 $1.59 Disposed 121548 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-03-01 Restricted Stock Unit (RSU) $ M 7875 Disposed 2027-03-01 Common Stock (7875) Direct
2025-03-01 Restricted Stock Unit (RSU) $ M 17250 Disposed 2028-03-01 Common Stock (17250) Direct

Footnotes

F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.

F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F3: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date.

F4: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date.